| Title | Statins and bone formation: proposed methods of implementing statins innovation in osteoporosis | ||
| Authors | M. Mironidou-Tzouveleki and Ch. Dokos
A’ Laboratory of Pharmacology, Medical School, Aristotle University, Thessaloniki, Greece |
||
| Citation | Mironidou-Tzouveleki, M., Dokos, C.: Statins and bone formation: proposed methods of implementing statins innovation in osteoporosis, Epitheorese Klin. Farmakol. Farmakokinet. 22(2): 254-255 (2008) | ||
| Publication Date | 23-25 May 2008 | ||
| Full Text Language | English | ||
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
||
| Keywords | Statins, bone formation, osteoporosis, skin patches, nanocarriers, route of administration. | ||
| Other Terms | Review article | ||
| Summary | Statins are well validated class of agents that is used to modulate lipid levels in blood. Experimental studies indicate that they exhibit beneficial properties beyond lowering cholesterol levels. It seems that they have anti-inflammatory, angiogenetic, antithrombotic, antioxidant, antiproliferative, anti-tumor and bone formation properties. Lipophilic statins (simvastatin, lovastatin and cerivastatin) are highly absorbed by skeletal bone tissue, increase mRNA levels of BMP-2 and bone formation biochemical markers. According to these data prenylation of specific G-heterotrimeric proteins is the basic proposed mechanism for statins bone formation properties. However clinical results are still controversial. Factors such as low biodistribution of statins (extended first passage metabolism by hepatic enzymes), obesity status, lipophilicity/hydrophilicity of statins, the genetic background of patient (mutations of drug metabolism’s hepatic enzymes), concomitant therapies (e.g. vitamin D), the amount of lipid lowering, the degree and duration of pro-hyperlipidemia seem to have hardly any clinical study. Statins act in a primary stage of cholesterol synthesis like bisphosphonates so it is proposed creating agents of chemical structure similar to prototype statins. Skin patches and nanocarriers may be helpful for better biodistribution of statins in bone. | ||
| References | 1. Dokos C., Myronidou-Tzouveleki M.: SERMs: the lovely multi-potential drugs targeting osteoporosis? Rev. Clin. Pharmacol. Pharmacokinet. 21: 75-81 (2007)
2. Perez-Castrilon J.L., Abas L., Vega G., Sanzi-Cantalapiedra A., Sanchez S., Hernandez G., et al.: Effects of statins on bone markers, bone mineral density and fractures. Possible role in osteoporosis treatment. Curr. Pharm. Anal. 2: 161-168 (2006) 3. Hamerman D.: Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies. Q. J. Med. 98: 467-484 (2005) 4. Jordan J.: Good vibrations and strong bone? Am. J. Physiol. Regulatory Integrative Comp. Physiol. 288: 555-556 (2005) 5. Mundy G.R.: Statins and their potential for osteoporosis. Bone 29: 495-497 (2001) 6. Moghadasian H.M., Frohlich J.J.: Statins and bones. CMAJ 154: 802-805 (2001) 7. Horiuchi N., Maeda T.: Statins and bone metabolism. Oral Diseases 12: 85-101 (2006) 8. Soubrier M., Roux C.: Statins in rheumatology. Joint Bone Spine 73: 159-168 (2006) 9. Garrett R.I., Mundy R.G.: The role of statins as potential targets for bone formation. Arthritis Res. 4: 237-240 (2002) 10. Cruz C.A., Gruber L.B.: Statins and osteoporosis: can these lipid-lowering drugs also bolster bones? Cleveland Drug J. Med. 59: 277-288 (2002) 11. Ellsworth J.A., Witt M.D., Dugdale D., Oliver M.L.: Mosby’s 2006 Medical Drug Reference. Philadelphia, Elsevier Mosby, 2006 12. Kasugai S.: Local application of statin for bone augmentation. Clin. Calcium 15: 67-72 (2005) 13. Gutierrez G.E., Lalka D., Garrett I.R., Rossini G., Mundy G.R.: Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations. Osteoporos. Int. 17: 1033-1042 (2006) 14. Dokos C., Mironidou-Tzouveleki M.: New trends and prospects of nanotechonology application in drug delivery. Epitheor. Klin. Farmakol. Farmakokinet. 24: 165-172 (2006) |
||
| Relative Papers | |||
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2008 – ANNUAL SUBSCRIPTION 2008 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|